FDA approves Novartis’ leukemia treatment Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML), Aggressive Systemic Mastocytosis, Approvals, Blood Disorders, FDA, FDA/Regulatory, Genetics, Mast Cell Leukemia, Mutations The U.S. FDA approved Novartis AG’s Rydapt as an initial treatment for acute myeloid leukemia (AML) as well as certain other blood disorders. Read more April 28, 2017/by Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Reuters Health2017-04-28 10:41:502017-04-28 12:59:38FDA approves Novartis' leukemia treatment
